Al San­drock prunes his post-Bio­gen voy­age with sim­i­lar fo­cus on ALS

Al San­drock is nar­row­ing the fo­cus of Voy­ager Ther­a­peu­tics, con­cen­trat­ing on CNS dis­eases that were the hall­mark of his time lead­ing R&D at Bio­gen, in­clud­ing an em­pha­sis on a fa­mil­ial form of ALS for which his for­mer em­ploy­er is get­ting a speedy re­view at the FDA.

Less than six months in­to his jour­ney as CEO at Voy­ager, San­drock is fo­cus­ing the pre­clin­i­cal pipeline on Alzheimer’s dis­ease, GBA1 Parkin­son’s dis­ease and SOD1 amy­otroph­ic lat­er­al scle­ro­sis, the rare form of ALS for which the FDA will de­cide whether to ap­prove Bio­gen’s tofersen by Jan. 25, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER